Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

by Vergnenègre, Alain, Ray, Joshua A, Chouaid, Christos, Grossi, Francesco, Bischoff, Helge G, Heigener, David F, Walzer, Stefan
Published 2012

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

by Walleser, Silke, Ray, Joshua, Bischoff, Helge, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener, David, de Castro Carpeño, Javier, Tiseo, Marcello, Walzer, Stefan
Published 2012